Search the Newsreel

Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9%

Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9% Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 32.4% year on year to $219.1 million. The company's full-year revenue guidance of $875 …

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock, tax-free transaction to create a leading diversified central nervous system (CNS) biopharmaceutical company. The combined entity, to be named Supernus, Inc., is expected to have approximately $2.2 billion in annual revenues and generate $125 …

Understanding Momentum Shifts in (SUPN)

This article analyzes Supernus Pharmaceuticals Inc. (SUPN) using AI models, highlighting a neutral near-term sentiment and potential mid-term weakness. It identifies a breakdown underway, suggesting lower levels and elevated downside risk. The report provides specific institutional trading strategies, including long, breakout, and short positions, …

Supernus Pharmaceuticals (SUPN) awards 2,500 performance share units

Supernus Pharmaceuticals' Sr. VP of IP, CSO Padmanabh P. Bhatt, was awarded 2,500 Performance Share Units on July 29, 2026. These units, which were part of an award from February 19, 2025, vested upon the achievement of individual performance objectives set on May 3, …

Supernus Pharmaceuticals (NASDAQ: SUPN) CEO granted 29,849 performance share units

Supernus Pharmaceuticals CEO Jack A. Khattar was granted 29,849 Performance Share Units on July 29, 2026, which correspond to one share of common stock each. These units, awarded on February 19, 2025, vested upon the achievement of individual performance objectives established on May 3, …

Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for

Amphastar Pharmaceuticals (AMPH) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare …

Supernus Pharmaceuticals Inc (SUPN) Financial Health: Profitability & Balance Sheet Analysis

Supernus Pharmaceuticals Inc (SUPN) currently holds a financial score of 7.52, ranking 111th out of 155 in the Pharmaceuticals industry, indicating stable financial health and high operating efficiency. The company recently reported a quarterly revenue of $207.71 million, marking a 38.63% year-over-year increase, and …

Supernus Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

Supernus Pharmaceuticals (NASDAQ: SUPN) had 793 employees as of March 2026, representing a 25.8% decline from 2023. The company is actively hiring, with 105 job postings in 2026, and its workforce is primarily concentrated in the United States. Employee sentiment is neutral but improving, …

How Investors Are Reacting To Supernus Pharmaceuticals (SUPN) Positive Earnings ESP And Renewed Beat Expectations

Supernus Pharmaceuticals (SUPN) is attracting investor attention due to a positive Earnings ESP and a history of beating earnings expectations ahead of its early August 2026 release. While this fuels optimism for another beat, the core investment narrative relies on the company's ability to …

Supernus Pharmaceuticals (SUPN) Expected to Beat Earnings Estimates: Should You Buy?

Supernus Pharmaceuticals (SUPN) is projected to report a year-over-year decline in earnings but higher revenues for the quarter ended June 2026. The company has an Earnings ESP of +18.52% and a Zacks Rank #3, indicating a high probability of beating the consensus EPS estimate …

Supernus Pharmaceuticals, Inc. Revenue Breakdown – GETTEX:S49

Supernus Pharmaceuticals, Inc. (GETTEX:S49) generated 612.13 million EUR in revenue last year, primarily from its Central Nervous System Disease Treatments segment. The United States was the company's largest regional contributor to this revenue. This financial data shows a slight decrease from the previous year's …

Is Rising Earnings Optimism Altering The Investment Case For Supernus Pharmaceuticals (SUPN)?

Supernus Pharmaceuticals recently drew attention after analysts became more optimistic about its upcoming August 4, 2026 earnings report, citing a positive Earnings ESP of 18.52% and the company's track record of exceeding consensus in its last two quarters. This shift in sentiment highlights how …

Supernus Pharmaceuticals (SUPN) Could Be 25% Undervalued On Rising Earnings Expectations

Supernus Pharmaceuticals (SUPN) is considered undervalued by 25% due to rising earnings expectations, with a positive Earnings ESP of 18.52% and a history of beating estimates. Analysts peg the fair value at $62.83, significantly higher than its current share price of $46.98. This valuation …

Supernus Pharmaceuticals (SUPN) Projected to Release Earnings on Tuesday

Will Supernus (SUPN) Beat Estimates Again in Its Next Earnings Report?

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Supernus Pharmaceuticals (SUPN). This company, which is in the Zacks …

Supernus Pharmaceuticals Inc (SUPN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Supernus Pharmaceuticals Inc (SUPN) focusing on its dividend and stock split history. It notes that the company has not distributed dividends totaling 0.00 USD over the past five years and contains no data on past dividend payments or …

Supernus Pharmaceuticals Inc (SUPN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey

This article provides a detailed revenue breakdown for Supernus Pharmaceuticals Inc (SUPN), presenting its financial performance by business segments and regional contributions. The data covers various fiscal years and quarters, highlighting key product sales such as Qelbree, GOCOVRI, APOKYN, and Trokendi XR, along with …

SUPN|Supernus Pharmaceuticals Inc|Price:47.496|Chg%:+1.296

Supernus Pharmaceuticals Inc (SUPN) shows healthy fundamentals and high growth potential, despite a recent turnaround to a loss. The stock is considered fairly valued within the Pharmaceuticals industry, with high institutional ownership and multiple "Buy" ratings from analysts, setting a highest price target of …

Supernus CEO and CFO to host Aug. 4 second-quarter webcast

Supernus Pharmaceuticals announced that its CEO, Jack Khattar, and CFO, Tim Dec, will host a conference call and webcast on August 4, 2026, at 4:30 p.m. ET to discuss the company's second-quarter 2026 financial and business results. The results will be reported after the …

Supernus Pharmaceuticals to Announce Q2 2026 Financial Results and Host Investor Conference Call on August 4, 2026 1 – Minichart

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) will announce its second quarter 2026 financial results after market close on Tuesday, August 4, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. ET, led by President & CEO Jack …

Supernus to Report Q2 2026 Results, Conference Call Scheduled for August 4

Supernus Pharmaceuticals (SUPN) will report its second-quarter 2026 financial and business results after market close on Tuesday, August 4, 2026. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring remarks from management followed by a …

Supernus Pharmaceuticals to Announce Second Quarter 2026

Supernus Pharmaceuticals will announce its second-quarter 2026 financial results after market close on Tuesday, August 4, 2026. President and CEO Jack Khattar and Senior Vice President and CFO Tim Dec will host a conference call and webcast at 4:30 p.m. ET on the same …

Supernus Pharmaceuticals (SUPN) Could Be 24% Undervalued If Its CNS Pipeline Delivers

Supernus Pharmaceuticals (SUPN) has seen recent share price fluctuations but shows a 46.5% one-year total return. The company is considered 23.8% undervalued by Simply Wall St, with a fair value of $62.83 compared to its last close of $47.87, contingent on the success of …

Avoiding Lag: Real-Time Signals in (SUPN) Movement

This article provides a real-time analysis of Supernus Pharmaceuticals Inc. (SUPN) stock movement, highlighting strong sentiment in near and mid-term horizons. It presents an exceptional risk-reward setup, institutional trading strategies (Long, Momentum Breakout, Risk Hedging), and multi-timeframe signal analysis, all generated by AI models. …

ETFs Investing in Supernus Pharmaceuticals, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold Supernus Pharmaceuticals, Inc. (S49) stocks, sorted by market value. It provides detailed financial data for each ETF, including market value, weight of S49, issuer, management style, expense ratio, AUM, price, change percentage, relative volume, …

Non-Stimulant ADHD Drug Qelbree Reaches 3 Million Prescriptions

Supernus Pharmaceuticals is celebrating the five-year anniversary of the FDA approval of Qelbree, a once-daily, non-stimulant ADHD treatment for patients aged 6 and older. Since its launch, Qelbree has seen approximately 3 million prescriptions filled, with over 1 million in 2025 alone, establishing itself …

Supernus marks five years since Qelbree ADHD drug approval By Investing.com

Supernus Pharmaceuticals announced the five-year anniversary of its ADHD drug Qelbree's FDA approval, highlighting its non-stimulant nature and significant prescription growth, with 3 million filled globally and over 1 million in 2025 alone. The drug, approved for pediatric and adult patients, has contributed to …